Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Dose-finding, Positive-controlled, Double-blind, Double-dummy Phase II Clinical Trial to Evaluate the Efficacy and Safety of HRS5580 for Injection Combined With Palonosetron Hydrochloride in the Prevention of Postoperative Nausea and Vomiting

NCT07709897 is registered in ClinicalTrials.gov with Fujian Shengdi Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07709897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07709897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Dose-finding, Positive-controlled, Double-blind, Double-dummy Phase II Clinical Trial to Evaluate the Efficacy and Safety of HRS5580 for Injection Combined With Palonosetron Hydrochloride in the Prevention of Postoperative Nausea and Vomiting
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
August 6, 2026
Completion date
December 31, 2026
Enrollment
260 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of postoperative nausea and vomiting